Total Funding
94
94
Total FundingSeries C raised
Growth Score
7 pts
Heat Score
26 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
522
NewLimit is a biotech company developing epigenetic therapies to extend human healthspan by reprogramming aging cells.
- Greg Johnson: Co-Founder & Head of Machine Learning
- Jacob Kimmel: Co-founder & Head of Research
About the Company
NewLimit is a biotechnology company that focuses on extending human healthspan through epigenetic reprogramming of cells. The company develops innovative medicines aimed at restoring youthful function in aging cells, targeting age-related diseases. NewLimit employs cutting-edge research to explore the potential of cellular rejuvenation,
contributing to advancements in biomedicine. By utilizing epigenetic techniques, the company seeks to provide solutions that enhance the quality of life as individuals age. Its approach represents a significant shift in how age-related conditions are understood and treated, paving the way for new therapeutic options.
